There has been no Lyme disease vaccine for people since 2002. One existed before that, worked reasonably well, and was withdrawn from the market by its maker after demand collapsed amid safety claims that never held up. In the quarter century since, the only prevention on offer has been long sleeves, tick checks and repellent, while roughly 476,000 Americans a year are diagnosed with the disease.

In March, the two companies developing a replacement reported results from its pivotal trial. The vaccine prevented about three quarters of confirmed cases. It also narrowly failed the statistical test its primary endpoint was built around, which is the part worth understanding.

From the Lab to the Ledger

Lyme disease is caused by bacteria in the Borrelia burgdorferi group, carried by ticks. The vaccine target is a protein called OspA, which sits on the bacterial surface while the organism is still inside the tick's gut. Antibodies against OspA neutralize the bacteria during feeding, before they reach the person. It is an unusual mechanism: the vaccine works inside the tick rather than inside the patient.

The complication is that OspA comes in variants. The withdrawn 1998 vaccine covered the single variant dominant in North America. The current candidate, developed under the names VLA15 and now LB6V, covers six OspA serotypes, chosen as the most prevalent across both North America and Europe. That breadth is what would make it usable on two continents.

The pivotal trial, called VALOR, enrolled participants aged five and older at sites in high-incidence areas of the United States, Canada and Europe, randomized one to one against saline placebo. The schedule is four doses: months zero, two and five to nine, then a fourth dose a year later, timed just before the following tick season.

Two prespecified analyses were reported. Efficacy from 28 days after the fourth dose, the primary endpoint, was 73.2 percent, with a 95 percent confidence interval running from 15.8 to 93.5. The trial's success criterion required the lower bound of that interval to exceed 20, and 15.8 does not. A second analysis, from one day after the fourth dose, gave 74.8 percent efficacy with an interval of 21.7 to 93.9, which does clear the bar. The companies attribute the wide intervals to fewer Lyme cases accruing than expected, and say they are planning regulatory submissions.

Bio-Pipeline Ledger

LB6V, formerly VLA15: a six-valent OspA protein subunit vaccine with roughly 73 to 75 percent efficacy against confirmed Lyme disease in a completed Phase 3, reported as well tolerated with no safety concerns identified at the time of analysis. Regulatory submissions planned, with no agency decision and no approval anywhere.

LYMERix: the 1998 vaccine, reported in a trial at the time to reduce infections substantially, withdrawn by its manufacturer in 2002 after demand fell. No longer available and not returning.

Moderna's mRNA Lyme candidate: an earlier-stage programme with a Phase 1/2 trial recruiting. Early clinical stage, nothing established.

Post-exposure doxycycline: a single dose after a high-risk tick bite, used in defined circumstances. Validated for that narrow indication and unchanged by any of this.

Tick avoidance and prompt removal: unglamorous, free, and the only prevention that currently exists for humans.

The Clinical Reality Check

The honest reading of VALOR is a vaccine that probably works and a trial that could not prove it to its own predetermined standard. Those are not the same thing, and both halves matter. An efficacy estimate of 73 percent with a lower bound near 16 percent means the true effect could plausibly be modest, and the only way to narrow that is more cases or more data.

The reason the intervals are wide is itself informative. Lyme incidence varies enormously by year and by site, and a trial powered on expected case counts is at the mercy of a quiet season. This is a recurring problem for vaccines against regional, weather-dependent infections, and it is not evidence of anything wrong with the product.

What happens next sits with regulators, who will weigh a strong point estimate against a missed criterion. The companies have said they intend to file. Nobody should plan around a vaccination appointment on that basis.

For now, nothing about tick season changes. Repellent on skin and permethrin on clothing, a check of the whole body after time in grass or leaf litter, and prompt removal of attached ticks remain the entire toolkit. People in high-incidence areas who find an attached tick should ask a physician about post-exposure doxycycline rather than waiting for symptoms, because that decision has a short window and the vaccine conversation does not yet exist.

The signal worth following over the next year is a regulatory filing and then a decision, not another analysis of the same trial. If a vaccine does arrive, the four-dose schedule timed to tick season makes it a planning exercise rather than a walk-in appointment.